{"id":"furmonertinib-mesilate-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Furmonertinib selectively targets epidermal growth factor receptor (EGFR) mutations commonly found in non-small cell lung cancer, particularly overcoming resistance mechanisms like the T790M mutation that render first and second-generation EGFR inhibitors ineffective. By irreversibly binding to the ATP-binding pocket of mutant EGFR, it suppresses downstream signaling pathways that drive cancer cell proliferation and survival.","oneSentence":"Furmonertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:38.116Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with EGFR mutations, including T790M resistance mutations"}]},"trialDetails":[{"nctId":"NCT06970639","phase":"PHASE3","title":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-09-26","conditions":"NSCLC Patients With Brain Metastasis","enrollment":380},{"nctId":"NCT07169994","phase":"PHASE1, PHASE2","title":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2025-09-02","conditions":"Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer","enrollment":414},{"nctId":"NCT06962865","phase":"PHASE2","title":"A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2025-06-30","conditions":"Non-Small Cell Lung Cancer","enrollment":80},{"nctId":"NCT04671303","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-01-01","conditions":"Lung Cancer","enrollment":36},{"nctId":"NCT06868732","phase":"PHASE1","title":"Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-03-12","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":288},{"nctId":"NCT06352502","phase":"","title":"An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2022-01-28","conditions":"EGF-R Positive Non-Small Cell Lung Cancer, CNS Metastases","enrollment":30},{"nctId":"NCT06339242","phase":"PHASE2","title":"A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2024-01-01","conditions":"NSCLC","enrollment":30},{"nctId":"NCT05813522","phase":"PHASE2","title":"Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-04-15","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT03926182","phase":"PHASE1","title":"Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2019-02-19","conditions":"Healthy Male Volunteers","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AST2818"],"phase":"phase_3","status":"active","brandName":"Furmonertinib Mesilate Tablets","genericName":"Furmonertinib Mesilate Tablets","companyName":"Allist Pharmaceuticals, Inc.","companyId":"allist-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Furmonertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations. Used for Non-small cell lung cancer with EGFR mutations, including T790M resistance mutations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}